ClinicalTrials.gg

Program

JSKN016

A development code. Also written as “JSKN016 Injection” and “JSKN016 injection”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Triple Negative Breast Neoplasms · Breast Neoplasms, led by Alphamab Oncology.

Furthest: phase 3, since Mar 17, 20265 company-led studies, 5 open or runningNext primary completion: Jun 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alphamab Oncology55 open or runningphase 3since Mar 17, 2026Apr 28, 2024Jun 30, 2027phase 2 · NCT06942234

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 28, 2024First study: phase 1 study in Advanced Malignant Solid TumorFirst studyNCT06592417 · 140 planned · China
  2. Dec 30, 2024Phase 2 study in Advanced Non-small Cell Lung CancerNCT06775483 · 220 planned
  3. Mar 5, 2025Phase 1 study in Advanced Non-small Cell Lung CancerNCT06868732 · 288 planned · China
  4. Apr 10, 2025Phase 2 study in Inoperable Locally Advanced HER2-Negative Breast CancerNCT06942234 · 180 planned · China
  5. Mar 17, 2026Phase 3 study in Triple Negative Breast NeoplasmsPhase 3 reachedNCT07533123 · 364 planned · China

Ahead

  1. Jun 30, 2027Primary completion: phase 2 study in Inoperable Locally Advanced HER2-Negative Breast CancerNCT06942234
  2. Jun 30, 2027Primary completion: phase 2 study in Advanced Non-small Cell Lung CancerNCT06775483
  3. Jun 30, 2028Primary completion: phase 1 study in Advanced Non-small Cell Lung CancerNCT06868732
  4. Mar 17, 2029Primary completion: phase 3 study in Triple Negative Breast NeoplasmsNCT07533123

TargetBeta

“JSKN016 is a bispecific antibody drug conjugate targeting HER3 and TROP2.”study text, by rule · the study

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
JSKN016HCruleAlphamab Oncologyphase 11

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07533123Triple Negative Breast Neoplasms · China3RecruitingMar 17, 2029364
NCT06942234Inoperable Locally Advanced HER2-Negative Breast Cancer · China2RecruitingJun 30, 2027180
NCT06868732Advanced Non-small Cell Lung Cancer · China1RecruitingJun 30, 2028288
NCT06775483Advanced Non-small Cell Lung Cancer2Not yet recruitingJun 30, 2027220
NCT06592417Advanced Malignant Solid Tumor · China1RecruitingMay 17, 2026140

How it is read

Names in the registry

  • “JSKN016”, 3 entries
  • “JSKN016 Injection”, 1 entry
  • “JSKN016 injection”, 1 entry

Codes read as this program: JSKN016.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.